Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Talzenna
(United States) [Available]Synonyms :
talazoparib
Class :
Antineoplastics and PARP Inhibitors
Brand Name :
Talzenna
(United States) [Available]Synonyms :
talazoparib
Class :
Antineoplastics and PARP Inhibitors
1
mg
Capsule
Orally
once a day
Continue the therapy until disease progression or unacceptable toxicity occurs
Dose Adjustments
Renal Dose Adjustments: Mild: No adjustment recommended Moderate (CrCl 30-59 ml/min): 0.75 mg orally once a day Severe (CrCl 15-29 ml/min): 0.5 mg orally once a day Liver Dose Adjustments: No adjustment recommended
Safety and efficacy are not studied
Refer adult dosing
when both drugs are combined, there may be an increase in the serum concentration of talazoparib
may increase the serum concentration of talazoparib
when both drugs are combined, there may be an increase in the serum concentration of p-glycoprotein or abcb1 substrates
when both drugs are combined, there may be an increase in the serum concentration of talazoparib
verapamil may increase the serum concentration when combined with Talazoparib
when both drugs are combined, there may be a decrease in the therapeutic effect of bcg
when both drugs are combined, there may be increase in the serum concentration of talazoparib
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may enhance the serum concentration of BCRP/ABCG2 inhibitors
aminosalicylic acid derivatives
it may increase the effect of myelosuppressive agents
It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter
It may enhance the effect when combined with tafamidis meglumine
may enhance the serum concentration of P-glycoprotein/ABCB1 inhibitors
may enhance the serum concentration of BCRP/ABG2 inhibitors
may increase the CNS depressant effect of CNS depressants
Multipurpose enzymes known as poly (ADP-ribose) polymerases (PARPs) are involved in vital physiological processes.
PARPs use the base excision repair (BER) mechanism to identify and fix DNA single-strand breaks (SSBs).
BRCA1 and BRCA2 encode tumor suppressor proteins that use homologous recombination to repair DNA double-strand breaks (DSBs).
The buildup of unrepaired SSBs caused by talazoparib’s inhibition of the BER pathway results in the creation of DSBs, the most harmful type of DNA damage.
Adverse drug reactions:
Frequency defined
>10%
Fatigue
headache
dizziness
Alopecia
Increased serum glucose
decreased serum calcium
Nausea
vomiting
diarrhea
decreased appetite
abdominal pain
Decreased hemoglobin
anemia
neutropenia
thrombocytopenia
leukopenia
Increased serum aspartate aminotransferase
increased serum alkaline phosphatase
increased serum alanine aminotransferase
1-10%
Dysgeusia
dyspepsia
stomatitis
Lymphocytopenia
Frequency not defined
Bone marrow depression
None
Contraindication:
None
Caution:
Myelosuppression
Myelodysplastic syndrome
acute myeloid leukemia
Drug interactions
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Genomic instability and apoptotic cell death result from PARP inhibition in cancer cells with BRCA mutations.
A cytotoxic and anti-tumor agent is talazoparib. Talazoparib was cytotoxic in cancer cell lines with DNA repair gene abnormalities in vitro.
Patient-derived xenograft breast cancer models with mutant BRCA1 or BRCA2 showed anti-tumor effects mediated by talazoparib.
It is taken orally in tablet form with or without food.
Swallow hard capsules whole at time and do not open or dissolve it.
If the patient misses a dose or throws up, take the following dose at the scheduled time instead.
Patient information leaflet
Generic Name: talazoparib
Why do we use talazoparib?
Adult patients with deleterious or presumed deleterious HER2-negative breast cancer that is locally progressed or metastatic and has a germline BRCA mutation (gBRCAm) treated with talazoparib.
Talazoparib and enzalutamide are recommended for the treatment of adult patients with metastatic castration-resistant prostate cancer that has a mutation in the HRR gene.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
